Xtalks

Life sciences innovation continues to advance despite a more selective funding environment and evolving market conditions. While biotech companies are making progress in areas such as AI-enabled drug discovery, precision medicine and advanced therapeutics, organizations across the ecosystem are navigating new challenges around investment, commercialization and research infrastructure.

In this week’s episode of the Xtalks Life Science Podcast, host Soumya Shashikumar, Senior Life Sciences Journalist at Xtalks, spoke with Dr. Kia Moteshari, President and Chief Operating Officer of ReAlta Life Sciences, about the biology of hypoxic-ischemic encephalopathy (HIE) and the scientific, clinical and regulatory considerations shaping treatment development. HIE is a serious neonatal brain injury caused by insufficient oxygen and blood flow to the brain around the time of birth.

This privacy policy describes the privacy practices for www.Xtalks.com (hereafter referred to as “the Site”). Citizens of the UK and EU should refer to EU and UK – PRIVACY POLICY – HONEYCOMB WORLDWIDE INC. All users of the Site should read this privacy policy in conjunction with the Site’s TERMS OF USE. The Site is owned and operated by Honeycomb Worldwide Inc. (hereafter referred to as “Honeycomb”, “we”, “us” or “our”).

This privacy policy describes the privacy practices for www.Xtalks.com (hereafter referred to as “the Site”). Citizens of the UK and EU should refer to EU and UK – PRIVACY POLICY – HONEYCOMB WORLDWIDE INC. All users of the Site should read this privacy policy in conjunction with the Site’s TERMS OF USE. The Site is owned and operated by Honeycomb Worldwide Inc. (hereafter referred to as “Honeycomb”, “we”, “us” or “our”).

This privacy policy describes the privacy practices for www.Xtalks.com (hereafter referred to as “the Site”). Citizens of the UK and EU should refer to EU and UK – PRIVACY POLICY – HONEYCOMB WORLDWIDE INC. All users of the Site should read this privacy policy in conjunction with the Site’s TERMS OF USE. The Site is owned and operated by Honeycomb Worldwide Inc. (hereafter referred to as “Honeycomb”, “we”, “us” or “our”).

Pulmonary hypertension (PH) can be difficult to recognize, difficult to classify and, for many patients, difficult to access care for in time. Rather than a single disease, PH refers to a complex group of conditions marked by high blood pressure in the blood vessels of the lungs. It can occur on its own, as in pulmonary arterial hypertension (PAH), or develop as a complication of underlying heart or lung disease.

This privacy policy describes the privacy practices for www.Xtalks.com (hereafter referred to as “the Site”). Citizens of the UK and EU should refer to EU and UK – PRIVACY POLICY – HONEYCOMB WORLDWIDE INC. All users of the Site should read this privacy policy in conjunction with the Site’s TERMS OF USE. The Site is owned and operated by Honeycomb Worldwide Inc. (hereafter referred to as “Honeycomb”, “we”, “us” or “our”).

Breakthroughs in regenerative medicine are accelerating, but ensuring that these therapies reach patients in an accessible and affordable way remains a challenge for health systems worldwide. In Canada, these challenges are particularly pronounced, prompting the Stem Cell Network to launch a focused effort on access, affordability and adoption.

This privacy policy describes the privacy practices for www.Xtalks.com (hereafter referred to as “the Site”). Citizens of the UK and EU should refer to EU and UK – PRIVACY POLICY – HONEYCOMB WORLDWIDE INC. All users of the Site should read this privacy policy in conjunction with the Site’s TERMS OF USE. The Site is owned and operated by Honeycomb Worldwide Inc. (hereafter referred to as “Honeycomb”, “we”, “us” or “our”).

In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Dr. Tanya Petrossian, CEO and Founder of EndoCyclic Therapeutics, a biopharmaceutical company developing a non-hormonal therapeutic approach for endometriosis. Endometriosis affects many women, but it is still often difficult to diagnose, treat and fully understand.